HCWB HCW BIOLOGICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, HCW BIOLOGICS INC reported revenue of $122K (up 1758.5% from a year earlier), net income of −$5.22M and diluted EPS of −$11.58; over the last four quarters revenue was $6.66M and net income −$5.58M; for the fiscal year ended December 2025 revenue was $54.2K, down 97.9% on the year before.
HCWB annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $54.2K, gross profit $10.8K, operating income −$13.2M, net income −$7.96M (margin -14677.1%), EPS −$10.63
- Fiscal year ended Dec 2024: revenue $2.57M, gross profit $959K, operating income −$29.5M, net income −$30.0M (margin -1169.7%), EPS −$30.96
- Fiscal year ended Dec 2023: revenue $2.84M, gross profit $560K, operating income −$25.7M, net income −$25.0M (margin -879.5%), EPS −$0.70
- Fiscal year ended Dec 2022: revenue $6.72M, gross profit $2.59M, operating income −$15.1M, net income −$14.9M (margin -221.7%), EPS −$0.42
- Fiscal year ended Dec 2021: revenue $0, gross profit $0, operating income −$13.4M, net income −$12.9M (margin n/a), EPS −$0.69
HCWB quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $122K (up 1758.5% year over year), net income −$5.22M, EPS −$11.58
- Quarter ended Mar 31, 2026: revenue $6.50M (up 128231.7% year over year), net income $3.47M, EPS $1.39
- Quarter ended Dec 31, 2025 (from the annual report): revenue $27.0K (down 93.2% year over year), net income $719K, EPS $43.91
- Quarter ended Sep 30, 2025: revenue $15.6K (down 96.3% year over year), net income −$4.55M, EPS −$2.02
- Quarter ended Jun 30, 2025: revenue $6.55K (down 98.9% year over year), net income −$1.93M, EPS −$40.72
- Quarter ended Mar 31, 2025: revenue $5.07K (down 99.6% year over year), net income −$2.20M, EPS −$11.80
- Quarter ended Dec 31, 2024 (from the annual report): revenue $395K (down 70.2% year over year), net income −$3.37M, EPS −$10.47
- Quarter ended Sep 30, 2024: revenue $426K (down 50.0% year over year), net income −$3.90M, EPS −$4.13
- Quarter ended Jun 30, 2024: revenue $619K (down 0.6% year over year), net income −$15.3M, EPS −$16.16
- Quarter ended Mar 31, 2024: revenue $1.13M (up 2590.1% year over year), net income −$7.47M, EPS −$0.20
- Quarter ended Dec 31, 2023 (from the annual report): revenue $1.32M (down 1.3% year over year), net income −$10.7M, EPS −$0.30
- Quarter ended Sep 30, 2023: revenue $853K (down 52.8% year over year), net income −$4.94M, EPS −$0.14
- Quarter ended Jun 30, 2023: revenue $623K (up 37.2% year over year), net income −$4.30M, EPS −$0.12
- Quarter ended Mar 31, 2023: revenue $41.9K (down 98.7% year over year), net income −$5.07M, EPS −$0.14
- Quarter ended Dec 31, 2022 (from the annual report): revenue $1.34M, net income −$5.42M, EPS −$0.15
- Quarter ended Sep 30, 2022: revenue $1.81M, net income −$3.91M, EPS −$0.11
- Quarter ended Jun 30, 2022: revenue $454K, net income −$3.51M, EPS −$0.10
- Quarter ended Mar 31, 2022: revenue $3.12M, net income −$2.06M, EPS −$0.06
- Quarter ended Dec 31, 2021 (from the annual report): revenue $0, net income −$3.17M, EPS $0.80
- Quarter ended Sep 30, 2021: revenue $0, net income −$4.09M, EPS −$0.14
HCWB cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$13.4M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$14.2M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$22.5M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$10.4M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$11.0M, share buybacks n/a
HCWB balance sheet
- Jun 30, 2026: cash $741K, total assets $26.8M, total liabilities $19.3M, shareholders' equity $7.43M
- Mar 31, 2026: cash $1.23M, total assets $27.3M, total liabilities $21.6M, shareholders' equity $5.76M
- Dec 31, 2025: cash $1.95M, total assets $24.5M, total liabilities $21.8M, shareholders' equity $2.76M
- Sep 30, 2025: cash $1.10M, total assets $25.4M, total liabilities $27.6M, shareholders' equity −$2.11M
- Jun 30, 2025: cash $2.44M, total assets $28.9M, total liabilities $29.0M, shareholders' equity −$52.0K
- Mar 31, 2025: cash $1.11M, total assets $26.3M, total liabilities $34.8M, shareholders' equity −$8.56M
- Dec 31, 2024: cash $4.67M, total assets $30.2M, total liabilities $37.0M, shareholders' equity −$6.77M
- Sep 30, 2024: cash $998K, total assets $26.6M, total liabilities $36.5M, shareholders' equity −$9.97M
What is HCWB's revenue?
HCW BIOLOGICS INC reported $6.66M of revenue over its last four quarters, through June 30, 2026.
Is HCWB profitable?
No. HCW BIOLOGICS INC lost $5.58M over the last four quarters.
What is HCWB's EPS?
Diluted earnings per share over the last four quarters were $31.70; −$11.58 in the latest quarter.